MedTrace Logo

Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis

NCT06577077 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 432

Last updated 2024-08-29

No results posted yet for this study

Summary

To evaluate the efficacy and safety of CM9241GRU versus placebo in the treatment of perennial allergic rhinitis.

Conditions

  • Rhinitis, Allergic, Perennial

Interventions

DRUG

Product CM9241GRU

01 tablet in the morning and 01 tablet in the evening for 14 days

DRUG

Placebo

01 tablet in the morning and 01 tablet in the evening for 14 days

Sponsors & Collaborators

  • Ache Laboratorios Farmaceuticos S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2025-08-31
Completion
2025-08-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06577077 on ClinicalTrials.gov